ACM
PCRX icon

Asymmetry Capital Management’s Pacira BioSciences PCRX Stock Holding History

Asymmetry Capital Management’s Portfolio PCRX Stock Details PCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-84,735
Closed -$3.69M – 34
2019
Q2 		$3.69M Buy
84,735
+70,854
+510% +$3.01M 2% 19
2019
Q1 		$528K Buy
+13,881
New +$542K 0.88% 25
2016
Q3 		– Sell
-41,707
Closed -$1.41M – 21
2016
Q2 		$1.41M Buy
+41,707
New +$2.05M 2.58% 16

Other funds holding PCRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
PC
Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return
FCM
Frontier Capital Management Boston, Massachusetts $9.73B AUM 55.65% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
SIMG
Stephens Investment Management Group Houston, Texas $7.3B AUM 41.96% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Asymmetry Capital Management's PCRX Position: Q3 2019 in Review

Asymmetry Capital Management sold out of Pacira BioSciences (PCRX) in Q3 2019, closing a stake of 84,735 shares — an estimated $3.69M sold.

Asymmetry Capital Management first reported a position in PCRX in Q2 2016 and held it in 3 quarters. The position peaked at $3.69M in Q2 2019. 211 funds tracked by Wall St. Rank hold PCRX as of Q3 2019.

  • Asymmetry Capital Management reported no remaining Pacira BioSciences position as of Q3 2019 after selling out during the quarter.
  • Asymmetry Capital Management sold 84,735 Pacira BioSciences shares in Q3 2019, an estimated $3.69M.
  • Asymmetry Capital Management first reported a position in Pacira BioSciences in Q2 2016 and held it in 3 quarters.
  • Asymmetry Capital Management's Pacira BioSciences position peaked at $3.69M in Q2 2019.
  • 211 funds tracked by Wall St. Rank held Pacira BioSciences as of Q3 2019.

Based on Asymmetry Capital Management's 13F filing for Q3 2019, filed 12 Nov 2019.